clonidine has been researched along with betaxolol in 21 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (14.29) | 18.7374 |
| 1990's | 5 (23.81) | 18.2507 |
| 2000's | 9 (42.86) | 29.6817 |
| 2010's | 4 (19.05) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Gao, F; Lombardo, F; Obach, RS; Shalaeva, MY | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| Campillo, NE; Guerra, A; Páez, JA | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Enjaume, C; Pienkowski, C; Rochiccioli, P; Tauber, MT; Uboldi, F | 1 |
| Andermann, G; de Burlet, G; Himber, J | 1 |
| Pienkowski, C; Rochiccioli, P; Tauber, MT; Uboldi, F | 1 |
| Rochiccioli, P | 1 |
| Enjaume, C; Oliver, I; Pienkowski, C; Rochiccioli, P; Tauber, MT | 1 |
| Cepurna, WO; Johnson, E; Lauer, AK; Morrison, JC; Nylander, KB | 1 |
| Di Govanni, A; Fusco, R; Lamberti, G; Pignalosa, B; Pignalosa, G; Sebastiani, A | 1 |
| Kaya, M; Mete, U; Ozdemir, N; Polat, S; Soylu, M; Unlügenç, Z | 1 |
| Aston-Jones, G; Delfs, JM; Druhan, JP; Zhu, Y | 1 |
| Chao, HM; Chidlow, G; Melena, J; Osborne, NN; Wood, JP | 1 |
| Cantor, LB; Hoop, J; Katz, LJ; Lin, JC; Samuel, F; Spaeth, GL | 1 |
| Al-Hasani, R; Bruchas, MR; Foshage, AM; McCall, JG | 1 |
| Ajaltouni, Z; de Haro, L; Kervégant, M; Schmitt, C; Tauber, M; Tichadou, L | 1 |
1 review(s) available for clonidine and betaxolol
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
2 trial(s) available for clonidine and betaxolol
| Article | Year |
|---|---|
Short-term clinical trial evaluating the efficacy of the combination of apraclonidine 0.5% solution and betaxolol 0.25% suspension.
Topics: Adolescent; Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Adult; Aged; Betaxolol; Chronic Disease; Circadian Rhythm; Clonidine; Drug Therapy, Combination; Female; Follow-Up Studies; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Male; Middle Aged; Ophthalmic Solutions; Single-Blind Method; Suspensions; Treatment Outcome | 1997 |
The effect of topical glaucoma medications evaluated by perimetry.
Topics: Administration, Topical; Antihypertensive Agents; Betaxolol; Clonidine; Epinephrine; Glaucoma; Humans; Intraocular Pressure; Levobunolol; Prospective Studies; Sulfonamides; Thiophenes; Visual Field Tests | 2003 |
18 other study(ies) available for clonidine and betaxolol
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
Topics: Algorithms; Blood Proteins; Half-Life; Humans; Hydrogen-Ion Concentration; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Protein Binding; Statistics as Topic; Tissue Distribution | 2004 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
Topics: Administration, Oral; Humans; Models, Chemical; Neural Networks, Computer; Permeability; Quantitative Structure-Activity Relationship; Technology, Pharmaceutical | 2010 |
Association of pharmacological tests and study of 24-hour growth hormone secretion in the investigation of growth retardation in children: analysis of 257 cases.
Topics: Arginine; Betaxolol; Child; Clonidine; Female; Glucagon; Growth Disorders; Growth Hormone; Growth Hormone-Releasing Hormone; Humans; Insulin; Insulin-Like Growth Factor I; Male | 1991 |
Effects of adrenergic agents on alpha-chymotrypsin-induced ocular hypertension in albino and pigmented rabbits: a comparative study.
Topics: Adrenergic beta-Antagonists; Animals; Betaxolol; Chymotrypsin; Clonidine; Ocular Hypertension; Pigmentation; Propanolamines; Rabbits; Sympathomimetics | 1989 |
[Comparison of nyctohemeral somatotropin secretion and response to pharmacological tests in 38 children with growth retardation].
Topics: Adolescent; Betaxolol; Child; Child, Preschool; Circadian Rhythm; Clonidine; Dwarfism; Female; Glucagon; Growth Disorders; Growth Hormone; Humans; Male; Propanolamines | 1987 |
Comparison of pharmacological tests and 24-hour growth hormone secretion in 130 children with delayed growth.
Topics: Betaxolol; Child; Clonidine; Female; Glucagon; Growth Disorders; Growth Hormone; Humans; Male; Pituitary Function Tests; Propanolamines | 1987 |
[Statistic study of 5,473 somatotropin secretion stimulation pharmacologic tests (n=9). Proposed weighting coefficient].
Topics: Adolescent; Age Determination by Skeleton; Arginine; Betaxolol; Child; Child, Preschool; Clonidine; Confidence Intervals; Data Interpretation, Statistical; Female; Glucagon; Growth Disorders; Growth Hormone; Humans; Insulin; Levodopa; Male; Normal Distribution; Ornithine; Propranolol; Puberty; Radioimmunoassay; Retrospective Studies; Sensitivity and Specificity | 1993 |
Glaucoma drops control intraocular pressure and protect optic nerves in a rat model of glaucoma.
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Animals; Betaxolol; Clonidine; Disease Models, Animal; Glaucoma; Intraocular Pressure; Male; Nerve Fibers; Ocular Hypertension; Ophthalmic Solutions; Optic Nerve; Optic Nerve Diseases; Rats; Rats, Inbred BN; Tonometry, Ocular | 1998 |
Ultrastructural effects of topical beta-adrenergic antagonists and an alpha-adrenergic agonist on the rabbit cornea.
Topics: Administration, Topical; Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Animals; Betaxolol; Clonidine; Cornea; Cytoplasm; Endoplasmic Reticulum; Levobunolol; Microvilli; Ophthalmic Solutions; Rabbits; Timolol | 1999 |
Noradrenaline in the ventral forebrain is critical for opiate withdrawal-induced aversion.
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Amygdala; Animals; Betaxolol; Clonidine; Male; Narcotics; Neurons, Afferent; Norepinephrine; Propanolamines; Propranolol; Prosencephalon; Rats; Rats, Sprague-Dawley; Substance Withdrawal Syndrome; Tyrosine 3-Monooxygenase | 2000 |
An investigation into the potential mechanisms underlying the neuroprotective effect of clonidine in the retina.
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Animals; Batrachotoxins; Betaxolol; Calcium Channel Blockers; Cerebral Cortex; Chick Embryo; Clonidine; Fibroblast Growth Factor 2; Neuroprotective Agents; Neurotoxins; Nitrendipine; Rabbits; Rats; Rats, Wistar; Reactive Oxygen Species; Retina; RNA, Messenger; Saxitoxin; Sodium Channels | 2000 |
Locus coeruleus kappa-opioid receptors modulate reinstatement of cocaine place preference through a noradrenergic mechanism.
Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Adrenergic alpha-2 Receptor Agonists; Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-Antagonists; Animals; Betaxolol; Clonidine; Cocaine; Conditioning, Psychological; Drug-Seeking Behavior; Locus Coeruleus; Male; Mice; Mice, Inbred C57BL; Naltrexone; Propanolamines; Propranolol; Receptors, Adrenergic, alpha; Receptors, Adrenergic, beta; Receptors, Opioid, kappa | 2013 |
[Clonidine poisoning in a child: a case report].
Topics: Adrenergic alpha-2 Receptor Agonists; Albuterol; Antihypertensive Agents; Betaxolol; Blood Pressure; Child; Clonidine; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Overdose; Drug Therapy, Combination; Heart Rate; Humans; Male; Medication Errors; Naloxone | 2014 |